BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 13, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 4, 2019
View Archived Issues
GP-205 shows promising preclinical profile supporting further development as HCV infection therapy
Read More
Activation-induced cytidine deaminase mediates T790M resistance mutation to TKI-treated lung cancer
Read More
E7 oncogene expression sensitizes to an Aurora kinase inhibitor in HPV+ head and neck cancer
Read More
Microenvironment-on-a-chip brings new insights into Herceptin
Read More
Analogues K2A and R13A of mutacin 1140 demonstrate efficacy in animal models of MRSA infection
Read More
Medshine Discovery divulges new angiotensin AT2 receptor antagonists
Read More
Bristol-Myers Squibb patents formylpeptide FPR1 and FPR2 receptor agonists
Read More
Synthon Biopharmaceuticals patents anti-SHPS-1 antibodies
Read More
Bayer and DKFZ present MAP4K1 inhibitors
Read More
Checkpoint protein promotes NASH, may represent new therapeutic target
Read More
Sesen Bio presents positive preliminary data from registration phase III VISTA study
Read More
Pivotal trial of inebilizumab achieves primary and key secondary endpoints
Read More
Discovery and characterization of novel CID peptidomimetic, DB-550
Read More
First cohort dosed in phase I study of PLN-74809
Read More
Merus and Betta Pharmaceuticals enter agreement to develop MCLA-129 in China
Read More
Urovant initiates phase IIa study of vibegron for IBS-related abdominal pain
Read More
NanoFlu elicits promising immune responses in phase II trial
Read More
Jounce completes first cohort enrollment in phase I study of JTX-4014 in solid tumors
Read More
Five new Japanese approvals for Keytruda
Read More
Horizon Pharma and HemoShear Therapeutics to jointly discover therapeutics for gout
Read More
Knopp Biosciences Baylor College of Medicine to develop treatments for KCNQ2 neonatal encephalopathy
Read More
Mutations in ROBO4 gene tied to bicuspid aortic valve and thoracic aortic aneurysm
Read More
Evelo begins phase I/II trial of EDP-1503 in combination with Keytruda
Read More
